Eye Melanoma Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The eye melanoma market size has grown strongly in recent years. It will grow from $9.1 billion in 2024 to $9.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs.

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $13.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging.

The projected rise in eye cancer cases is poised to be a significant driver for the eye melanoma market's expansion in the coming years. Eye cancer denotes the abnormal and uncontrolled growth of cells within the eye's structures. Enhanced detection techniques, increased awareness, and advancements in treatment options have led to a heightened demand for specialized therapies and interventions to effectively manage early cases. For example, according to the American Cancer Society's January 2023 report, eye and orbital cancer cases increased to 3,490 in 2023, marking a 5.12% growth from 3,320 in 2021. Therefore, the surge in eye cancer cases is expected to fuel the growth of the eye melanoma market.

The anticipated growth in the geriatric population is set to boost the eye melanoma market's expansion in the foreseeable future. Eye melanoma, a form of eye cancer, tends to become more prevalent with age due to prolonged exposure to environmental factors and genetic predispositions among older individuals. The expanding population of older adults increases the potential number of individuals susceptible to eye melanoma. As reported by the World Health Organization in October 2022, the population aged 60 and above surged from 1 billion in 2021 to 1.4 billion in 2022, with projections to double to 2.1 billion by 2050. Hence, the growing geriatric population is expected to drive the growth of the eye melanoma market.

Companies at the forefront of the eye melanoma treatment sector are dedicated to pioneering innovative and specialized treatments, particularly immunotherapies and targeted therapies, aiming to elevate patient outcomes and improve their quality of life. These novel treatment modalities have recently made significant strides in the field of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm specializing in soluble T-cell receptor technology for biological drug development, obtained approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). This groundbreaking therapy, the first of its kind for individuals with unresectable or metastatic uveal melanoma (mUM), operates as an immunotherapy targeting the gp100 protein found on the surface of uveal melanoma cells. By activating the patient's immune system through engineered T-cell receptors, Kimmtrak enables a precision-focused approach to eliminating melanoma, leveraging specialized immune cells for cancer treatment.

In January 2023, Health Network One, a leading US-based specialty benefit management company, acquired Premier Eye Care for an undisclosed amount. This acquisition enables Health Network One to broaden its provider network, improve clinical quality, and foster innovation in ophthalmology services. Premier Eye Care, a US-based company, specializes in diagnosing and treating eye melanoma through various methods such as surgery, radiation, and laser therapy.

Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc, Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd., IDEAYA Biosciences, Immunocore Limited, Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.

North America was the largest region in the eye melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Eye melanoma is a form of cancer that develops in the melanocytes, the cells responsible for producing melanin within the eye. This cancer can manifest in different parts of the eye, including the uvea, iris, and choroid. Eye melanoma stands as the most common primary intraocular cancer in adults and may lead to vision issues, alterations in eye color, and other symptoms, depending on its location and size.

The primary types of eye melanoma are found in the uvea, sclera, and retina. The uvea constitutes the middle layer of the eye, encompassing the iris, ciliary body, and choroid, housing blood vessels that supply nutrients to the eye. Various forms of radiation therapy, such as plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are employed to target and reduce the size of uveal melanomas. Diagnosis involves imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and other approaches. These treatments are typically administered by end users such as hospitals, clinics, and academic institutes.

The eye melanoma market research report is one of a series of new reports that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with an eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.